BGM0504
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
BrightGene Bio-Medical Technology Co · Phase 2 · Recruiting · Enrollment 200
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| The dose1 group | n/r | n/r | n/r | n/r |
| The dose2 group | n/r | n/r | n/r | n/r |
| The dose3 group | n/r | n/r | n/r | n/r |
| The dose4 group | n/r | n/r | n/r | n/r |
| Placebo group | n/r | n/r | n/r | n/r |
Not shown
- The dose1 group: endpoint not reported
- The dose2 group: endpoint not reported
- The dose3 group: endpoint not reported
- The dose4 group: endpoint not reported
- Placebo group: endpoint not reported